The company operates as a vertically integrated textile manufacturer that produces cotton yarn, grey fabric, dyed fabric, and denim for garment makers and traders.
The company operates in a highly fragmented and cyclical commodity textile market with no evidence of pricing power, as seen in the razor-thin net margins of 1.5%. While vertical integration provides some cost efficiency, the low ROCE of 9% suggests the lack of a durable competitive advantage.
Management has focused on vertical integration and capacity expansion, yet these investments have failed to generate returns significantly above the cost of capital. The company relies on preferential allotments to promoters to fund debt repayment and working capital rather than generating sufficient internal cash flow for growth.
The business collapsed as the razor-thin 1.5% net margins were entirely consumed by rising interest costs and cyclical downturns in the commodity textile market. Management's inability to generate internal cash flow led to a spiral of dilutive preferential allotments and high-interest debt to fund working capital. Ultimately, the lack of internal controls and the history of regulatory friction culminated in a total loss of investor confidence, as related-party transactions and governance failures drained what little equity remained.
RichFakir rates United Polyfab Gujarat Ltd's business quality as poor — 35/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, United Polyfab Gujarat Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on United Polyfab Gujarat Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of United Polyfab Gujarat Ltd's fair value is about ₹10 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →